Careers  |  Sign In  |  Register

Adding Ilixadencel Improved Outcomes in Metastatic Renal Cell Carcinoma

Study Presentations

A study composed of patients from across the USA and Europe observed improved outcomes in those treated with both ilixadencel and sunitinib compared with sunitinib alone. Magnus Lindskog, MD, PhD, of Uppsala (Sweden) University Hospital, reported these results at the ASCO-SITC Immuno-Oncology Symposium. The treatment appears to be well tolerated, with ilixadencel not appearing to cause any additional serious adverse events.

Learn more by clicking here.